Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 469-472

  Saleri, Nuccia ^a,b   Dembélé, Sary Mathurin ^a   Villani, Paola ^c   Carvalho, Anna Cristina C ^b   Cusato, Maria ^c   Bonkoungou, Victor ^a   Nacanabo, Rachel ^a   Kouanda, Seni ^d   Comelli, Mario ^e   Regazzi, Mario ^c   Matteelli, Alberto ^b  

^a Ministry of Health   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c IRCCS   (Italy)

^d National Research Institute   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

HAART; Pharmacokinetics; TB

Indexed keywords

ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BURKINA FASO; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LONGITUDINAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; PROSPECTIVE STUDY; SHORT COURSE THERAPY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BURKINA FASO; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETHAMBUTOL; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PLASMA; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 84855857591     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr445     Document Type: Article

References (22)

1. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
2. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-51.
3. Barroso EC, Pinheiro VG, Façanha MC et al. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg 2009; 81: 322-9.
4. Boulanger C, Hollender E, Farrell K et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49: 1305-11.
5. Sahai J, Gallicano K, Swick L et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127: 289-93.
6. Gurumurthy P, Ramachandran G, Hemanth Kumar AK et al. Decreased bioavailability of rifampicin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48: 4473-5.
7. Chideya S, Winston CA, Peloquin CA et al. Isoniazid, rifampicin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48: 1685-94.
8. Matteelli A, Saleri N, Villani P et al. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients co-infected with HIV-1 and tuberculosis. J Acquir Immune Defic Syndr 2009; 52: 64-9.
9. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC). The Hague: Tuberculosis Coalition for Technical Assistance, 2006. http://www.who.int/tb/publications/2006/ istc_report.pdf (19 September 2011, date last accessed).
10. Peloquin CA. Rifampin stability. Ther Drug Monit 1998; 20: 450-1.
11. Allanson AL, Cotton MM, Tettey JN et al. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J Pharm Biomed Anal 2007; 44: 963-9.
12. Weiner M, Benator D, Burman W et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-91.
13. Wen B, Chen Y, Fitch WL. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P4503A4. Drug Metab Dispos 2009; 37: 1557-62.
14. Chen J, Mannargudi BM, Xu L et al. Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem Res Toxicol 2008; 21: 1862-70.
15. Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51: 3781-8.
16. Jayaram R, Gaonkar S, Kaur P et al. Pharmacokineticspharmacodynamics of rifampicin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-24.
17. Peloquin CA, Namdar R, Singleton MD et al. Pharmacokinetics of rifampicin under fasting conditions, with food and with antacids. Chest 1999; 115: 12-8.
18. Choudhri SH, Hawken M, Gathua S et al. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 1997; 25: 104-11.
19. Taylor B, Smith PJ. Does AIDS impair the absorption of antituberculosis agents? Int J Tuberc Lung Dis 1998; 2: 670-5.
20. Berning SE, Huitt GA, Iseman MD et al. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992; 327: 1817-8.
21. Rana SV, Gupta D, Vaiphei K et al. Effect of mild malnutrition on dissaccaridase activity and glucose uptake in intestinal brush border vesicles of growing monkeys. Scand J Gastroenterol 1995; 30: 451-5.
22. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV infected patients. N Engl J Med 1995; 332: 336-7.